Press Reports on Possible MS Cure: Research on Potential Strategy to Repair Myelin —No Human Studies Until 2020
June 12, 2017
Early studies in mice on the immune messenger protein “LIF,” leukemia inhibitory factor, have recently been covered in the press as a possible cure for multiple sclerosis. This protein shows potential for both regulating the immune response that goes awry in MS, and stimulating the repair of damaged nerve-insulating myelin. In 2015, a team of researchers from the University of Cambridge, University of Edinburgh and Yale University reported these findings, noting that by using an advanced system involving tiny “nanoparticles,” they could deliver LIF to immature myelin-making cells in mice, and promote their maturation and ability to form new myelin.
Further laboratory work on this approach is necessary before it can be tested in people. Clinical trials in people with MS are not scheduled to begin before 2020, according to LIFNano Therapeutics, a company established by the University of Cambridge researchers.
“I am encouraged by these results in early phase laboratory studies,” says Bruce Bebo, Phd, Executive Vice President of Research at the National MS Society. “We look forward to seeing further studies that establish LIF as a target for strategies that can safely repair nervous system damage in people with MS.”
Read the 2015 study from this team
Read more about research to repair damage in MS
Multiple sclerosis is an unpredictable disease of the central nervous system. Currently there is no cure. Symptoms vary from person to person and may include disabling fatigue, mobility challenges, cognitive changes, and vision issues. An estimated 1 million people live with MS in the United States. Early diagnosis and treatment are critical to minimize disability. Significant progress is being made to achieve a world free of MS.